GRPR and prostate carcinoma: Recently, a radiolabeled HBPL, being able to address the gastrin-releasing peptide receptor as well as integrin αvβ3 was successfully translated into the clinics for imaging of prostate cancer with PET/CT, showing a much higher tumor visualization sensitivity compared to the respective GRPR-targeting peptide monomer.